Neurology Xagena
New efficacy data for investigational Cladribine tablets were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ( ECTRIMS ), in London. The fi ...
New results from the REGAIN study, a global, placebo-controlled phase 3 registration trial of Eculizumab ( Soliris ) in patients with refractory generalized myasthenia gravis ( gMG ), were presented a ...
A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 ( PCSK9 ) inhibitors Alirocumab and Evolocumab. Researchers have inve ...
New research from researchers based at The Westmead Institute in Sydney has drawn a link between the genetic and environmental circumstances of multiple sclerosis, which affects 2.1 million people wor ...
Traumatic brain injury with a loss of consciousness may be associated with later development of Parkinson's disease but not Alzheimer's disease or incident dementia, according to a study conducted at ...
The results from the phase 2 SYNERGY study evaluating Opicinumab ( anti-LINGO-1 ), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people ...
The pathogenesis of rosacea is unclear, but increased matrix metalloproteinase target tissue activity appears to play an important role. Parkinson disease and other neurodegenerative disorders also di ...
Northwestern Medicine researchers have discovered a new cause of Parkinson's disease, mutations in a gene called TMEM230. This appears to be the third gene definitively linked to confirmed cases of th ...
A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 ( Nrf2 ) / antioxidant response element signaling, which regulates expression of antioxidant, anti- ...
Runs of premature atrial complexes ( PACs ) are common in stroke patients and perceived to be clinically insignificant, but their prognostic significance is unclear. A study has investigated the ass ...
A study has evaluated the efficacy and tolerability of intravenous Lacosamide ( LCM-iv ) under routine conditions in daily clinical practice as a prospective registry. Patients with any type of sei ...
Few studies have systematically investigated insomnia in adults with epilepsy. Researchers have performed a prospective cross-sectional investigation of the prevalence, severity, and comorbidities ...
White matter is diffusely altered in tuberous sclerosis complex ( TSC ), and these alterations appear to be more evident in subjects with a more severe neurologic phenotype. However, little is known ...
Adipokines, especially leptin and adiponectin, have gained increasing importance in pathophysiology of various neurological diseases including epilepsy. There are experimental data suggesting a role ...
The aim of a study was to evaluate the efficacy and safety of the new antiepileptic drug Brivaracetam ( Briviact ) as add-on treatment for drug-resistant partial epilepsy using meta-analytical techniq ...
A new way of using MRI scanners to look for evidence of multiple sclerosis in the brain has been successfully tested by researchers at The University of Nottingham and Nottingham University Hospitals ...
Men who have high levels of urate, also known as uric acid, in their blood may be less likely to develop Parkinson’s disease, according to a study published in the Neurology, the medical journal of th ...
Brivaracetam ( UCB 34714; Briviact ) is an add-on treatment for adult patients with partial seizures. Similar to Levetiracetam ( Keppra ), Brivaracetam acts as a high-affinity ligand of the synaptic v ...
The objective of a study was to reach consensus among physicians treating patients with Parkinson's disease ( PD ) regarding key patient characteristics that indicate transition to advanced PD ( APD ) ...
The use of Cannabis with higher delta9-tetrahydrocannabinol content has been associated with greater risk, and earlier onset, of psychosis. However, the effect of Cannabis potency on brain morphology ...
The hepatitis C virus may be associated with an increased risk of developing Parkinson’s disease, according to a study published in the Neurology, the medical journal of the American Academy of Neurol ...
Researchers from the University of Sheffield in collaboration with researchers from the University of York have discovered a drug which has already been in use for decades to treat liver disease. The ...
New results from a prespecified interim analysis of PRIME, the phase 1b placebo-controlled study of Aducanumab in patients with prodromal or mild Alzheimer’s disease, were presented at the Alzheimer’s ...
New results from a 684-subject phase 2b clinical trial evaluating RVT-101, as an adjunctive therapy to Donepezil in patients with mild-to-moderate Alzheimer's disease, were presented at the 2015 Alzhe ...
Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...
Therapeutic repair of myelin disorders may be limited by the relatively slow rate of human oligodendrocyte differentiation. To identify appropriate pharmacological targets with which to accelerate ...
Roche has announced positive results from two pivotal studies evaluating the investigational medicine Ocrelizumab compared with Interferon beta-1a ( Rebif ), a standard-of-care therapy, in people with ...
The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa ) in March 2011, and three more NOACs, Rivaroxaban ( Xarelto ), Apixaban ( Eli ...
Although multiple sclerosis is thought to represent an excessive and inappropriate immune response to several central nervous system ( CNS ) autoantigens, increasing evidence also suggests that multip ...
Multiple sclerosis is triggered by self-reactive T cells that successfully infiltrate the brain and spinal cord where they launch an aggressive autoimmune attack against myelin. Over time, the resulti ...
Modern scientific understanding has considered multiple sclerosis to be a disease controlled by the T cell, a type of white blood cell. Research has shown that in multiple sclerosis, T cells inappropr ...
The phase 3 ASCEND study investigating Natalizumab ( Tysabri ) in the treatment of secondary progressive multiple sclerosis ( SPMS ) did not achieve its primary and secondary endpoints. During the stu ...
The purpose was to report the effects of delayed-release Dimethyl fumarate ( DMF; also known as gastro-resistant DMF ) on the number of relapses requiring intravenous ( IV ) steroids and multiple scle ...
Uric acid may lessen women’s disability after stroke, according to new research published in Stroke, journal of American Heart Association ( AHA ). High levels of Uric acid can lead to kidney ston ...
Researchers have analyzed the evolution of non-motor symptoms and patients’ and neurologists’ clinical global impression ( CGI ) in advanced Parkinson's disease patients treated with Levodopa–Carbidop ...
Extensive published evidence supports the use of subcutaneously-administered Apomorphine as an effective therapy for Parkinson's disease ( PD ) but to date no consensus recommendations have been avail ...
A study has compared the effectiveness ( percentage of change in daily ON, OFF and dyskinesia times ) and tolerability of Levodopa-Carbidopa intestinal gel ( LCIG; Duodopa; Duopa ) in patients with Pa ...
The aim of a study was to compare the safety and efficacy of Botulinum toxin type-A ( BTX-A ) versus anticholinergic therapy as Biperiden HCl in the treatment of cervical dystonia patients. After f ...
Pooling of efficacy data across studies can provide a more precise estimate of overall treatment effect, treatment effect for endpoints measured infrequently, and variation of effect across subgroups ...
Researchers have evaluated the efficacy and the safety of a prolonged release oral formulation of Oxycodone hydrochloride combined with Naloxone hydrochloride dehydrate, in a fixed ratio of 2:1 ( OXN ...
A study has compared baseline characteristics between patients with advanced Parkinson's disease who continued with Levodopa-Carbidopa intestinal gel [ LCIG; Duodopa; Duopa ] ( contLCIG ) and patients ...
Levodopa-Carbidopa intestinal gel ( LCIG ) was evaluated for the treatment of dyskinesia in a subgroup of advanced Parkinson’s disease ( PD ) patients with relevant dyskinesia. Oral Levodopa therap ...
Biotin, used at high dose, has some impact on disease progression and permanent disability in patients with progressive multiple sclerosis. Overall, 21/23 patients ( 91.3% ) exhibited some qualitative ...
No drug has been found to have any impact on progressive multiple sclerosis ( MS ). Biotin is a vitamin acting as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids ...
In a study published in The Journal of Experimental Medicine, researchers, at the Wihuri Research Institute and the University of Helsinki, have reported a surprising finding that challenges current a ...
Cardiovascular disease is a recognized contributor to the pathogenesis of Alzheimer's disease. Heart failure is a cardiovascular subtype that can be used to model the contribution of cardiovascular di ...
Positive results from the pivotal phase III clinical trial, MS-SPI were presented at the American Academy of Neurology Annual Meeting. The study demonstrated evidence of the efficacy and safety of M ...
Cysteine could potentially lower the risk of stroke through antihypertensive and antioxidant effects. A study has evaluated the hypothesis that cysteine intake is inversely associated with stroke in ...
Twenty-three patients aged from 26 to 75 years ( mean=52.8 years ) were treated with high doses of Biotin from 2 to 36 months ( mean treatment׳s duration=9.2 months ). Fourteen patients suffered fro ...
A research presented at the International Stroke Conference ( ISC ) and published in The New England Journal of Medicine ( NEJM ) found that the addition of the Solitaire Device stent thrombectomy pro ...
2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati
